High Free Cash Flow Stocks
TCMD is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
TACTILE SYSTEMS TECHNOLOGY I (TCMD) Stock Price & Overview
NASDAQ:TCMD • US87357P1003
Current stock price
24.6 USD
-1.37 (-5.28%)
At close:
24.6 USD
0 (0%)
After Hours:
The current stock price of TCMD is 24.6 USD. Today TCMD is down by -5.28%. In the past month the price decreased by -16.35%. In the past year, price increased by 86.5%.
TCMD Key Statistics
52-Week Range8.61 - 37.77
Current TCMD stock price positioned within its 52-week range.
1-Month Range24.24 - 29.06
Current TCMD stock price positioned within its 1-month range.
- Market Cap
- 552.024M
- P/E
- 29.64
- Fwd P/E
- 21.23
- EPS (TTM)
- 0.83
- Dividend Yield
- N/A
TCMD Stock Performance
Today
-5.28%
1 Week
-8.14%
1 Month
-16.36%
3 Months
-10.22%
Longer-term
6 Months +61.84%
1 Year +86.50%
2 Years +78.65%
3 Years +34.94%
5 Years -57.07%
10 Years N/A
TCMD Stock Chart
TCMD Stock Screens
TCMD currently appears in the following ChartMill screener lists.
TCMD Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to TCMD. When comparing the yearly performance of all stocks, TCMD is one of the better performing stocks in the market, outperforming 86.05% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
TCMD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to TCMD. TCMD has an excellent financial health rating, but there are some minor concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TCMD Earnings
On February 17, 2026 TCMD reported an EPS of 0.46 and a revenue of 103.59M. The company beat EPS expectations (2.5% surprise) and beat revenue expectations (8.27% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 17, 2026
PeriodQ4 / 2025
EPS Reported$0.46
Revenue Reported103.594M
EPS Surprise 2.50%
Revenue Surprise 8.27%
TCMD Forecast & Estimates
11 analysts have analysed TCMD and the average price target is 38.76 USD. This implies a price increase of 57.56% is expected in the next year compared to the current price of 24.6.
For the next year, analysts expect an EPS growth of 39.6% and a revenue growth 12.76% for TCMD
Analysts
Analysts83.64
Price Target38.76 (57.56%)
EPS Next Y39.6%
Revenue Next Year12.76%
TCMD Groups
Sector & Classification
TCMD Financial Highlights
Over the last trailing twelve months TCMD reported a non-GAAP Earnings per Share(EPS) of 0.83. The EPS increased by 16.9% compared to the year before.
Income Statements
Revenue(TTM)329.52M
Net Income(TTM)19.09M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.79% | ||
| ROA | 6.97% | ||
| ROE | 8.72% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%15%
Sales Q2Q%21.04%
EPS 1Y (TTM)16.9%
Revenue 1Y (TTM)12.47%
TCMD Ownership
Ownership
Inst Owners99.15%
Shares22.44M
Float21.72M
Ins Owners3.15%
Short Float %8.74%
Short Ratio5.54
TCMD Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 17.91 | 178.754B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.23 | 160.562B | ||
| SYK | STRYKER CORP | 21.92 | 126.877B | ||
| BSX | BOSTON SCIENTIFIC CORP | 17.96 | 93.218B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.9 | 47.074B | ||
| IDXX | IDEXX LABORATORIES INC | 38.42 | 45.348B | ||
| BDX | BECTON DICKINSON AND CO | 11.33 | 43.995B | ||
| RMD | RESMED INC | 18.25 | 32.645B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.61 | 32.062B | ||
| DXCM | DEXCOM INC | 24.47 | 23.946B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.72 | 17.783B | ||
| HOLX | HOLOGIC INC | 15.41 | 16.888B | ||
| PODD | INSULET CORP | 31.6 | 14.383B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TCMD
Company Profile
Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 1,086 full-time employees. The company went IPO on 2016-07-28. The firm's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. The company is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The company also offers Kylee, a free mobile application that helps patients learn about lymphedema.
Company Info
IPO: 2016-07-28
TACTILE SYSTEMS TECHNOLOGY I
3701 Wayzata Blvd, Suite 300
Minneapolis MINNESOTA 55416 US
CEO: Daniel L. Reuvers
Employees: 1086
Phone: 18333822845
TACTILE SYSTEMS TECHNOLOGY I / TCMD FAQ
Can you describe the business of TACTILE SYSTEMS TECHNOLOGY I?
Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 1,086 full-time employees. The company went IPO on 2016-07-28. The firm's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. The company is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The company also offers Kylee, a free mobile application that helps patients learn about lymphedema.
What is the stock price of TACTILE SYSTEMS TECHNOLOGY I today?
The current stock price of TCMD is 24.6 USD. The price decreased by -5.28% in the last trading session.
Does TACTILE SYSTEMS TECHNOLOGY I pay dividends?
TCMD does not pay a dividend.
What is the ChartMill rating of TACTILE SYSTEMS TECHNOLOGY I stock?
TCMD has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the market cap for TACTILE SYSTEMS TECHNOLOGY I?
TACTILE SYSTEMS TECHNOLOGY I (TCMD) has a market capitalization of 552.02M USD. This makes TCMD a Small Cap stock.
What is the next earnings date for TCMD stock?
TACTILE SYSTEMS TECHNOLOGY I (TCMD) will report earnings on 2026-05-04.
What is the outstanding short interest for TACTILE SYSTEMS TECHNOLOGY I?
The outstanding short interest for TACTILE SYSTEMS TECHNOLOGY I (TCMD) is 8.74% of its float.